ENABLING NEXT-GEN BIOLOGICS

ENABLING NEXT-GEN BIOLOGICS

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It’s FastPharming™ and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce COVID-19 biologics.

IN THE NEWS

August 10, 2020

iBio Provides Update on IBIO-201 COVID-19 Vaccine Program

IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies NEW ...

June 24, 2020

TEXAS A&M TESTS COVID-19 VACCINE CANDIDATES FOR IBIO, INC.

by tamus | Jun 24, 2020 | System News       Chancellor Sharp praises partnership between ...

June 24, 2020

iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates

iBio Granted 18 Months of Free Access to IBM’s Clinical Trial Management System NEW YORK, June 24, ...